Amarin Corporation plc (NASDAQ: AMRN) today announced that final study-related visits have commenced for patients enrolled in its REDUCE-IT cardiovascular ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Bullish Options Bias in Amarin Corp. (AMRN) Targets Upside in Shares -SusquehannaMarch 5, 2018 3:20 PM Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes StudyMarch 1, 2018 5:00 AM Amarin Corp. (AMRN) Misses Q4 EPS by 4c, Beats on RevenuesFebruary 27, 2018 5:39 AM